Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.65 · Revenue $498.18M · 5 analysts
Est. EPS $0.63 · Revenue $499.14M · 5 analysts
Est. EPS $2.35 · Revenue $1.96B · 5 analysts
Est. EPS $0.44 · Revenue $488.50M · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.9B | -4.9% | +2.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $165.4M | +266.9% | +34.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +24.7% | +9.2% | +14.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +12.1% | +453.7% | +19.3% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +8.6% | +275.6% | +31.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $252.6M | +36.9% | +191.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +13.2% | +44.0% | +189.1% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 76.3% | -11.9% | -1.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.66x | +12.9% | -0.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.2B | +4.4% | +2.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 1.94 vs 2.08 | -6.9% | 0.49 vs 0.65 | -24.6% |
| Revenue Surprise | $1.9B vs $1.9B | +0.5% | $487.8M vs $498.2M | -2.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Young Sylvia Jean | director | Common Stock | D | 18,500 | $26.62 |
| Aug 12, 2026 | McEachin Thomas | director | Common Stock | A | 472 | $26.50 |
| Aug 12, 2026 | Weis Shirley A | director | Common Stock | A | 472 | $26.50 |
| Aug 12, 2026 | Starcher John M. Jr. | director | Common Stock | A | 472 | $26.50 |
| Aug 12, 2026 | Linynsky Laura A | director | Common Stock | A | 472 | $26.50 |
Operator: Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q2 2026 Pediatrix Medical Group Inc. Earnings Conference Call. [Operator Instructions] I'd now like to turn the call over to [ Ashley Schneider ]. Please go ahead. Unknown Attendee: Good morning. Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and assessments made by Pediatrix's management in light of their experience and assessment of historic trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements made during this call are made as of today, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the company's filings with the SEC, including the sections entitled Risk Factors. In today's remarks by management, they will be discussing non-GAAP financial metrics. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures can be found in this morning's earnings press release and the company's quarterly and annual reports and on the Pediatrics website at www.pediatrix.com. With that, I will turn the call over to Mark Ordan, Chief Executive Officer of Pediatrics Medical Group. Mark Ordan: Thank you, Ashley, and good morning, everyone. Also with me today is Kasandra Rossi, our Chief Financial Officer. We are pleased to report another solid quarter with adjusted EBITDA of $76 million. Same unit revenue was buoyed by strong RCM collections, payer mix, and importantly, continuing rise in acuity, while we did see modestly lower volumes, primarily in neonatology with NICU days down 3%. Our overall results for the quarter were in line with our expectations, and we reaffirm our full year 2026 outlook of $280 million to $300 million in adjusted EBITDA. In the quarter, we repurchased just under 2 million shares of our stock, bringing our total buybacks since August of 2025 to 7 million shares and our shares outstanding to 81 million, down from $87 million at the end of the second quarter of 2025. Our cash balance is at $289 million with total debt of $584 million. We've spoken before about our financial strength, which enables our consistent support for our practices, quality programs, research and growth. Before Kasandra provides additional details on the quarter, I'll comment on how the pieces of our business fit our strategic position. You know our sector-leading footprint in neonatology and maternal-fetal medicine. Today, we are in the process of building a …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Mark S. Ordan | Chief Executive Officer & Executive Chairman | USD 5,718,327 | Male | 1959 | Active |
D. Gregory Neeb | Executive VP & Chief Operating and Strategy Officer | USD 1,748,025 | Male | 1968 | Active |
Mary Ann E. Moore | Advisor | USD 1,639,216 | Female | 1960 | Active |
Kasandra H. Rossi | Executive Vice President, Treasurer & Chief Financial Officer | USD 1,261,761 | Female | 1973 | Active |
John C. Pepia | Senior Vice President & Chief Accounting Officer | USD 931,198 | Male | 1963 | Active |
David Haddock | Executive Vice President, General Counsel & Secretary | — | Male | — | Active |
Cheryl VanPatten | Senior Vice President & Chief Information Officer | — | Female | — | Active |
Debra McRoberts | Senior Vice President of People Services | — | Female | — | Active |
Michael Dwyer | Chief Medical Officer of South Central Division | — | — | — | Active |
Mike Ashford | President of South Central Division | — | Male | — | Active |
Kevin Pitzer | President of West Division | — | Male | — | Active |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

Pediatrix Medical Group NYSE: MD reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management collections, payer mix and patient acuity offset lower patient-service volumes.

Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.53 per share a year ago.
